Currently, there are 89.00M common shares owned by the public and among those 86.06M shares have been available to trade.
The company’s stock has a 5-day price change of 39.28% and 77.89% over the past three months. ATYR shares are trading 48.90% year to date (YTD), with the 12-month market performance up to 206.25% higher. It has a 12-month low price of $1.42 and touched a high of $4.83 over the same period. ATYR has an average intraday trading volume of 1.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 45.63%, 59.38%, and 73.62% respectively.
Institutional ownership of Atyr Pharma Inc (NASDAQ: ATYR) shares accounts for 69.43% of the company’s 89.00M shares outstanding.
It has a market capitalization of $479.73M and a beta (3y monthly) value of 0.87. The earnings-per-share (ttm) stands at -$0.81. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.73% over the week and 5.63% over the month.
Analysts forecast that Atyr Pharma Inc (ATYR) will achieve an EPS of -0.18 for the current quarter, -0.15 for the next quarter and -0.57 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.25 while analysts give the company a high EPS estimate of -0.25. Comparatively, EPS for the current quarter was -0.23 a year ago. Earnings per share for the fiscal year are expected to increase by 23.15%, and 14.31% over the next financial year.
Looking at the support for the ATYR, a number of firms have released research notes about the stock. Leerink Partners stated their Outperform rating for the stock in a research note on February 18, 2025, with the firm’s price target at $16. Wells Fargo was of a view on October 04, 2024 that the stock is Overweight, while Jefferies gave the stock Buy rating on September 05, 2024, issuing a price target of $9. Oppenheimer on their part issued Perform rating on July 05, 2023.
